Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda

International Journal of Cancer

Volumn 139, Issue 3, 2016, Pages 518-526

  Franceschi, Silvia ^a   Chantal Umulisa, M ^b   Tshomo, Ugyen ^c   Gheit, Tarik ^a   Baussano, Iacopo ^a   Tenet, Vanessa ^a   Tshokey, Tshokey ^c   Gatera, Maurice ^b   Ngabo, Fidele ^b   Van Damme, Pierre ^d   Snijders, Peter J F ^e   Tommasino, Massimo ^a   Vorsters, Alex ^d   Clifford, Gary M ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Ministry of Health of Rwanda   (Rwanda)

^c Royal Government of Bhutan   (Bhutan)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bhutan; effectiveness; HPV; HPV vaccination; Rwanda; urine

Indexed keywords

PROTEIN E7; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN 5; VIRUS GLYCOPROTEIN 6; WART VIRUS VACCINE; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; BHUTAN; CHILD; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HEALTH SURVEY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTION; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLIC HEALTH CAMPAIGN; RWANDA; SCHOOL CHILD; SCHOOL HEALTH SERVICE; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; URINALYSIS; VIRUS DETECTION; WART VIRUS; ALPHAPAPILLOMAVIRUS; CLASSIFICATION; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTOR; URINE; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ALPHAPAPILLOMAVIRUS; BHUTAN; BIOMARKERS; CHILD; FEMALE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PREVALENCE; RISK FACTORS; RWANDA; URINALYSIS; VACCINATION; YOUNG ADULT;

EID: 84963553837     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30092     Document Type: Article

References (34)

1. Dorji T, Tshomo U, Phuntsho S, et al., Introduction of a National HPV vaccination program into Bhutan. Vaccine 2015; 33: 3726-30.
2. Binagwaho A, Ngabo F, Wagner CM, et al., Integration of comprehensive women's health programmes into health systems: cervical cancer prevention, care and control in Rwanda. Bull World Health Organ 2013; 91: 697-703.
3. Tshomo U, Franceschi S, Dorji D, et al., Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. BMC Infect Dis 2014; 14: 408
4. Ngabo F, Umulisa MC, Gatera M, et al., Monitoring HPV vaccine impact in Rwanda [POSTER]. 30th International Papillomavirus Conference & Clinical and Public Health Workshops, Lisbon, Portugal, 17-21 September 2015
5. Dhendup T, Tshering P., Cervical cancer knowledge and screening behaviors among female university graduates of year 2012 attending national graduate orientation program, Bhutan. BMC Womens Health 2014; 14: 44
6. Pathak N, Dodds J, Zamora J, et al., Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. Bmj 2014; 349: g5264
7. Vorsters A, Van den Bergh J, Micalessi I, et al., Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis 2014; 33: 2005-14. 10.1007/s10096-014-2147-2 [doi].
8. UNESCO. UIS.Stat. Available from: http://data.uis.unesco.org/. (Accessed on August 26, 2015)
9. Roda Husman AM, Snijders PJ, Stel HV, et al., Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 1995; 72: 412-7.
10. Jacobs MV, Walboomers JM, Snijders PJ, et al., Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000; 87: 221-7.
11. van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al., GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 779-87.
12. Schmitt M, Dondog B, Waterboer T, et al., Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 2010; 48: 143-9.
13. Halec G, Schmitt M, Dondog B, et al., Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer 2013; 132: 63-71.
14. Bellaminutti S, Seraceni S, De Seta F, et al. HPV and Chlamydia trachomatis co-detection in young asymptomatic women from high incidence area for cervical cancer. J Med Virol 2014; 86: 1920-5.
15. Eklund C, Zhou T, Dillner J., Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010; 48: 4147-55.
16. IARC. Biological agents. IARC Monogr Eval Carcinog Risks Hum 2012;100B:1-441. PM: 23189750. Available at: http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php
17. Herrero R, Wacholder S, Rodriguez AC, et al., Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011; 1: 408-19. 2159-8290.CD-11-0131 [pii];10.1158/2159-8290.CD-11-0131 [doi].
18. Drolet M, Benard E, Boily MC, et al., Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15: 565-80.
19. Sonnenberg P, Clifton S, Beddows S, et al., Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013; 382: 1795-806.
20. Kavanagh K, Sinka K, Cuschieri K, et al., Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis 2013; 13: 519-1471.
21. Brown DR, Kjaer SK, Sigurdsson K, et al., The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) l1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 Years. J Infect Dis 2009; 199: 926-35.
22. Wheeler CM, Kjaer SK, Sigurdsson K, et al., The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199: 936-44.
23. Appui Rwanda. Le système scolaire au Rwanda (2009). Available at: http://www.appuirwanda.org/040-le-systeme-scolaire-au-rwanda-2009.html. (Accessed on August 26, 2015).
24. Vorsters A, Micalessi I, Bilcke J, et al., Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis 2012; 31: 627-40.
25. Enerly E, Olofsson C, Nygard M., Monitoring human papillomavirus prevalence in urine samples: a review. Clin Epidemiol 2013; 5: 67-79.
26. Vorsters A, Van Keer S, Van Damme P., The use of urine in the follow-up of HPV vaccine trials. Hum Vaccin Immunother 2015; 11: 350-2.
27. Vorsters A, Van Damme P, Clifford G., Urine testing for HPV: rationale for using first void. Bmj 2014; 349: g6252
28. Sharma K, Kathait A, Jain A, et al., Higher prevalence of human papillomavirus infection in adolescent and young adult girls belonging to different Indian tribes with varied socio-sexual lifestyle. PLoS One 2015; 10: e0125693.
29. O'Leary MC, Sinka K, Robertson C, et al., HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland. Br J Cancer 2011; 104: 1221-6.
30. Bianchi S, Frati ER, Panatto D, et al., Detection and genotyping of human papillomavirus in urine samples from unvaccinated male and female adolescents in Italy. PLoS One 2013; 8: e79719.
31. UNICEF-MICS. MICS Surveys. Available at: http://mics.unicef.org/surveys. (Accessed on August 26, 2015).
32. Measure DHS., Demographic and Health Surveys. Available at: http://dhsprogram.com/What-We-Do/Survey-Types/DHS.cfm. (Accessed on August 24, 2015)
33. Republic of Rwanda. NewsDetails2: The Workforce Development Authority continues to empower individuals through skills development. Available at: http://www.gov.rw/newsdetails2/?tx-ttnews%5Btt-news%5D=288&cHash =dca53bc287639082d1ecf34ce3fd6a89. (Accessed on August 26, 2015)
34. Cuschieri K, Kavanagh K, Sinka K, et al., Effect of HPV assay choice on perceived prevalence in a population-based sample. Diagn Mol Pathol 2013; 22: 85-90.